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Imidazoline I1 receptor ligands activate hepatic adiponectin pathways
and thus improve insulin sensitivity
Maud Weiss, Djamil Benameur, Gaëlle Aubertin, Pascal Bousquet, Natha-
lie Niederhoffer, Hugues Greney
Université de Strasbourg, LNPCV, Faculté de Médecine, Strasbourg,
France
Metabolic syndrome is defined as a cluster of cardiovascular and metabolic
disorders. Previous studies in rat models of metabolic syndrome have demon-
strated that ligands selective for I1 imidazoline receptor (LNPs) increase
insulin sensitivity through central sympathoinhibition and an additional
peripheral effect attributable to adiponectin, a major insulin-sensitizer adipo-
kine. The objective of this study was to explore possible direct actions on
hepatocytes, one of the target cells of insulin and adiponectin.
Experiments were carried out in HepG2 cells, a cell line of hepatocytes. In
order to evaluate the effect of LNPs on insulin sensitivity, the activation (i.e.
phosphorylation) of a key actor of insulin pathways, AKT, was evaluated by
measuring the ratio pAKT/AKT by Western Blot. Similarly, the effect of
LNPs on adiponectin signaling was evaluated by measuring the rate of phos-
phorylation of the central kinase involved in adiponectin pathways, AMPK, by
Western Blot. Insulin (10 μM) induced the phosphorylation of AKT (pAKT/
AKT=0.49±0.16) compared to control without insulin (pAKT/AKT=0.11±0.03;
p≤0.05) whereas LNPs (1μM) alone did not. Interestingly, pretreatment by
LNPs (1 μM) during 60 min could potentiate the insulin-induced activation of
AKT: LNP509: pAKT/AKT=1.13±0.18 (p≤0.05 vs insulin alone); LNP599:
pAKT/AKT=1.23±0.16 (p=0.0545 vs insulin alone).
Concerning adiponectin signaling pathways, LNPs alone (from 10-9 M to
10-4 M) increased AMPK phosphorylation in a concentration- and time-depen-
dent manner. The maximal effect was obtained after 10 min exposure of LNPs
10 μM (untreated cells: pAMPK/AMPK=0.18±0.04; LNP 509 pAMPK/
AMPK=0.38±0.05 p≤0.05; LNP599 pAMPK/AMPK=0.46±0.17). These data
suggest that LNPs on hepatic cells activate adiponectin pathways and poten-
tiate insulin action. These two direct effects on insulin sensitive cells could
account for the ameliorated insulin sensitivity observed in vivo.
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Sodium-glucose cotransporters (SGLT) in the heart. Contribution of
SGLT-type of transport in hyperglycemia-induced signaling pathway
in adult cardiomyocytes
Anne Van Steenbergen, Magali Balteau, Jean-Louis Vanoverschelde,
Louis Hue, Sandrine Horman, Luc Bertrand, Christophe Beauloye
Université Catholique de Louvain, Woluwé-Saint-Lambert, Belgique
Background: Exposure to hyperglycemic conditions increases reactive
oxygen species (ROS) production in adult cardiomyocytes, inducing glucotox-
icity. This is due to an NADPH oxidase activation and more particularly the
NOX2 isoform. Our group has demonstrated that hyperglycemia-induced toxic
effect does not required glucose metabolism but results from glucose transport
through a SGLT type of transport. SGLT acts as glucose sensor. Seven SGLT
isoforms have been described (SGLT1 to 6 and SMIT1) but their expression
in the heart remains to be elucidated. The aim of this work is to study SGLT
isoforms expression in the heart and identify the isoform responsible for glu-
cotoxicity.
Methods: SGLT isoforms expression has been performed in heart extracts
(from rats, mice and humans) and in isolated cardiomyocytes (from rats and
mice) using PCR and westernblotting. The study of the contribution of each
isoforms to glucotoxicity is based on the substrates specifity of all these SGLT
isoforms.
Results: SGLT1, SGLT3 and SMIT1 are expressed in the heart and in car-
diomyocytes from rats and mice as well as in human heart. In human heart,
SGLT3 expression is marginal. SGLT4 is only expressed in rat heart. In pres-
ence of 5 mM glucose, rat cardiomyocytes exposure to high concentration of
galactose (16 mM, transported through SGLT1) does not activate NOX2. By
contrast, myo-inositol (16 mM, transported through SMIT1) completly repro-
duces hyperglycemic effects. Indeed, it favors p47phox translocation inducing
NOX2 activation and stimulates ROS production. This ROS production is
blocked by a NOX2 specific inhibitor (gp91dstat). Similar observation was
perfomed in mice cardiomyocytes.
Conclusion: SGLT1 and SMIT1 are expressed in rats, mice and human
cardiomyocytes. Increased transport through SMIT1 activates NOX2.
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Leucine, a potent inhibitor of cardiac glucose uptake
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Background: It was demonstrated that branched-chain amino acids like
leucine induce insulin resistance in muscle and adipose tissues. The mecha-
nism proposed to explain leucine action involves mTOR/p70S6K signaling.
This pathway can be activated by leucine and is implicated in the stimulation
of an insulin negative feedback loop. Knowing that insulin-resistance partici-
pates in diabetic cardiomyopathy, we were interested in studying leucine
effect in cardiomyocytes.
Methods: Primary cultured adult rat cardiomyocytes were pretreated with
different concentrations of leucine (from 1 to 10 mM) during different periods
of time (up to 20h) before being exposed to insulin (3x10-9 M, 30 min).
Results: In absence of leucine, insulin induced a 6-fold increase in glucose
uptake (0.31+/-0.04 vs. 0.05+/-0.01 μmoles/mg.h). This correlated with the
increase in phosphorylation state of PKB and AS160, both known to regulate
glucose transport downstream of insulin. Pre-incubation with leucine for 1 h
stimulated mTOR/p70S6K pathway resulting in the inhibiting phosphorylation
of IRS-1 located in the proximal insulin signaling pathway. This is accompanied
by a significant decrease in PKB and AS160 phosphorylation but, surprisingly,
insulin-stimulated glucose uptake was preserved (0.31+/–0.05 μmoles/mg.h). On
the other hand, a longer incubation (14h) with leucine induced a drastic decrease
in glucose transport (0.056+/–0.01 μmoles/mg.h). The mTOR/p70S6K inhibitor
rapamycin did not prevent this inhibition. Moreover, the non-metabolized leu-
cine analog BCH was able to stimulate mTOR/p70S6K pathway but had no
effect on the insulin-mediated stimulation of glucose uptake. By contrast, inter-
mediates of leucine catabolism, alpha-ketoisocaproate, acetoacetate and beta-
hydroxybutyrate, inhibited glucose uptake similarly to leucine.
Conclusion: Leucine catabolism reduces insulin-dependent glucose trans-
port independently of insulin signaling.
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Elevated plasma PCSK9 is equally detrimental for non-familial
hypercholesterolemic (non-FH) and heterozygous FH patients, irres-
pective of their LDL receptor defects
Gilles Lambert
Faculté de Médecine, Nantes, France
Objectives: Do elevated PCSK9 levels constitute an even greater risk for
people who already have reduced LDL receptor (LDLR) levels, such as het-
erozygous familial hypercholesterolemic (HeFH) patients?
Methods: Circulating PCSK9 was measured by ELISA in non-treated HeFH
patients carrying either a D206E (n=237), V408M (n=117), or D154N (n=38)
LDLR missense mutation and in normolipidemic controls (n=152). Skin fibro-
blasts and lymphocytes were isolated from a subset of patients and grown in 0·5%
serum and mevastatin with increasing amounts of recombinant PCSK9. LDLR
abundance at the cell surface was determined by flow cytometry.
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Results: PCSK9 dose-dependently reduced LDLR expression in control
and FH fibroblasts to similar extents, by up to 77±8% and 82±7%. Likewise,
PCSK9 reduced LDLR abundance by 39±8% in non-FH and by 45±10% in
HeFH lymphocytes, irrespective of their LDLR mutation status. We found
positive correlations of the same magnitude between PCSK9 and LDL-C in
controls (b=0·22, p=0·0003), D206E (b=0·20, p=0·0002), V408M (b=0·24,
p=0·0002), and D154N (b=0·25, p=0·048) HeFH patients. The strengths of
these associations were all similar.
Conclusion: Elevated PCSK9 levels are equally detrimental for HeFH and
non-FH patients: a 100ng/mL increase in PCSK9 will lead to an increase in
LDL-C of 0·20-0·25mmol/L in controls and HeFH alike, irrespective of their
LDLR mutation. This explains why non-FH and HeFH patients respond
equally well to monoclonal antibodies targeting PCSK9.
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Paraoxonase 1 activity, in the fructose-fed rats, in the presence and in
the absence of an antioxidant treatment with alpha-lipoic acid
Steliana Ghibu (1), Cristina Craciun (2), Claudiu Morgovan (3), Cristina
Mogosan (1), Maria Dronca (4)
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Introduction: Paraoxonase 1 (PON1) is an esterase synthesized by the
liver and secreted into the plasma, where it is associated with high density
lipoproteins (HDL). Its role is to protect LDL and HDL from oxidation, thus
preventing atherosclerosis. A decreased level of plasma PON1 activities has
been found in diabetes mellitus, cardiovascular disorders and chronic liver dis-
eases; but, it can also be influenced by diet and life-style. The purpose of this
study was to assess the PON1 activities in the insulin-resistant rats fed with a
fructose-enriched diet, in the presence and in the absence of an antioxidant
treatment with alpha-lipoic acid (AL).
Methods: 48 male Sprague-Dawley rats were randomized into two series:
rats fed for 3 months with standard chow (Control) or with standard chow sup-
plemented with fructose (60%). In each series, a group of rats was treated
intraperitoneally during 14 days/month with NaCl 0.9% and another group
with 50 mg/kg/day AL. At the end of the 3 months, we assessed: 1) peripheral
tissue resistance to insulin (HOMA-IR) and plasma lipid profile, 2) paraox-
onase, arylesterase and lactonase activities of PON1, 3) plasma homocysteine
(Hcy) level and 4) hepatic transaminase activities: aspartate-aminotransferase
and alanine-aminotransferase.
Results: The fructose intake increased peripheral tissue resistance to insulin
(HOMA-IR) and plasma lipoprotein level, less the HDL. Also, transaminase and
PON1 activities, especially arylesterase and lactonase activities, and the plasma
Hcy level were significantly (p>0.05) enhanced in the fructose group. The AL dis-
continuous treatment associated with the fructose-enriched diet improved the
tissue sensitivity to insulin and decreased the plasma lipoprotein levels. Moreover,
the AL treatment restored PON1 and transaminase activities, without influencing
the Hcy concentration. A decrease in plasma transaminase activities was noted
even when AL was associated with standard diet.
Conclusions: In our experimental conditions, the fructose intake induced
an increase in plasma transaminase and PON1 activities in association with a
Hyperhomocysteinemia. The AL treatment restored the enzymes’ activities
and had a hepatoprotective effect, but without influence on Hcy level.
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Hao Ling pu-erh tea attenuates lipid accumulation in primary culture
rat hepatocytes.
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Aim: Tea is one of the most consumed beverages in the world and its health-
promoting effects have been widely investigated.Lipid-lowering effects of pu-erh
tea have attracted growing interest.The importance of liver in lipid metabolism
prompted us to investigate the lipid-lowering properties of pu-erh tea in rat pri-
mary culture hepatocytes.We tested the effect of a Hao Ling pu-erh tea extract
(HLPT) and one of the major components of tea as Epigallocatechin-3-gallate
(EGCG) which is largely recognized as a hypolipidemic molecule.
Methods: HLPT: an infusion of Hao Ling pu-erh tea was lyophilized and
quantified for its composition in catechins by LC-MS. 24h after seeding on
collagen, rat hepatocytes in primary culture were treated for 24h with various
concentrations of HLPT(100,200,400,600 μg/ml) and EGCG(30,100 uM) and
compared to CyclosporinA (hyperlipidemic reference) and Clofibrate (hypo-
lipidemic drug used in human)(n=3 in triplicate).Lipid droplet accumulation
was measured by LipidTox staining and evaluated by fluorescence microscopy
on an ArrayScanXTI high Content Analysis Reader(Cellomics Inc.).
Results: We found that HLPT significantly prevented hepatocyte lipid
accumulation (-56%) and in the same proportion to Clofibrate.EGCG also sig-
nificantly attenuated lipid accumulation (-19%) but less than HLPT.
Conclusion: The main result of this study was to point out the major implica-
tion of liver cells in the hypolipidemic effects of HLPT.Moreover, we have shown
here that this effect was partly due to the EGCG, well known for its antioxidant
effects.However as we reported here that HLPT has a higher hypolipidemic effect
than EGCG alone, which means that EGCG acts in synergy with other HLPT
components such as theaflavins but this hypothesis has to be confirmed in further
experiments.In future, the variation of expression of genes involved in lipid metab-
olism (THRSP,LXR,PPar-α) by qPCR induced by HLPT will allow us to improve
the understanding of the effect induced by HLPT.
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Prevention of cardiovascular, renal and metabolic abnormalities by
soluble epoxide hydrolase inhibition in a murine model of type 2 diabetes
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Objective: Epoxyeicosatrienoic acids (EETs) are synthesized from arachi-
donic acid, notably in endothelial cells, and display attractive metabolic, vaso-
dilatory and anti-inflammatory properties. We demonstrated previously that
inhibiting EET degradation mediated by soluble epoxide hydrolase (sEH)
reduces hypertension and heart failure, and others reported that it improves
glucose homeostasis in type 2 diabetes. However, the impact of such strategy
on target organ damage in diabetes remains to be clarified.
Materials and methods: The pharmacological sEH inhibitor t-AUCB
(10 mg/l in drinking water) was administered for 8 weeks in mice subjected to a
high-fat diet (HFD, 60% fat) for 16 weeks. Mice on control chow diet (10% fat),
non-treated HFD mice and HFD mice treated with glibenclamide (80 mg/l) served
as controls.
Results: Glibenclamide and t-AUCB similarly prevented the increased fasting
glycemia in HFD mice (Control: 5.4±0.2; HFD: 8.0±0.8; HFD+GLI: 5.1±0.3;
HFD+t-AUCB: 5.6±0.2 mmol/L; p<0.05). However, only t-AUCB improved glu-
cose tolerance and decreased gluconeogenesis. In parallel, t-AUCB prevented adi-
pose tissue activation and dyslipidemia. Moreover, t-AUCB improved coronary
endothelial function and prevented diastolic dysfunction, as shown by echocar-
diography (E/A ratio; Control: 1.25±0.02; HFD: 1.05±0.03; HFD+GLI:
1.07±0.04; HFD+t-AUCB: 1.23±0.04; p<0.05) and invasive hemodynamics
(LVEDPVR; Control: 1.9±0.55; HFD: 3.8±0.61; HFD+GLI: 3.1±0.8; HFD+t-
AUCB: 1.88±0.2 mmHg/RVU; p<0.05). Finally, t-AUCB prevented the increased
urinary albumine-to-creatinine ratio and decreased renal inflammation.
Discussion: These results demonstrate that beyond its glucose-lowering
effects sEH inhibition improves coronary endothelial function, diastolic dys-
function and prevents early kidney damage in a murine model of type 2 dia-
betes. This positive impact on target organ damage and metabolic
homeostasis prompts sEH inhibition as a promising therapeutic perspective
in type 2 diabetes.
